  Antimalarial drugs are a powerful tool for malaria control and elimination.
Artemisinin-based combination therapies (ACTs) can reduce transmission when
widely distributed in a campaign setting. Modelling mass antimalarial campaigns
can elucidate how to most effectively deploy drug-based interventions and
quantitatively compare the effects of cure, prophylaxis, and
transmission-blocking in suppressing parasite prevalence. A previously
established agent-based model that includes innate and adaptive immunity was
used to simulate malaria infections and transmission. Pharmacokinetics of
artemether, lumefantrine, dihydroartemisinin, piperaquine, and primaquine were
modelled with a double-exponential distribution-elimination model including
weight-dependent parameters and age-dependent dosing. Drug killing of asexual
parasites and gametocytes was calibrated to clinical data. Mass distribution of
ACTs and primaquine was simulated with seasonal mosquito dynamics at a range of
transmission intensities. A single mass campaign with antimalarial drugs is
insufficient to permanently reduce malaria prevalence when transmission is
high. Current diagnostics are insufficiently sensitive to accurately identify
asymptomatic infections, and mass-screen-and-treat campaigns are much less
efficacious than mass drug administrations. Improving campaign coverage leads
to decreased prevalence one month after the end of the campaign, while
increasing compliance lengthens the duration of protection against reinfection.
Use of a long-lasting prophylactic as part of a mass drug administration
regimen confers the most benefit under conditions of high transmission and
moderately high coverage. Addition of primaquine can reduce prevalence but
exerts its largest effect when coupled with a long-lasting prophylactic.
